What is Novocuff?
Novocuff operates at the intersection of medical technology and maternal health, specifically targeting the reduction of preterm births caused by PPROM and cervical shortening. The company's proprietary device technology is engineered to provide a non-invasive solution for high-risk pregnancies, aiming to improve neonatal outcomes and reduce the long-term healthcare costs associated with premature delivery. By focusing on evidence-based interventions, Novocuff is carving out a distinct niche within the women's health sector, a market segment that has historically seen significant underinvestment despite its profound impact on public health outcomes.
How much funding has Novocuff raised?
Novocuff has raised a total of $52M across 2 funding rounds:
Series A
$26M
Series A
$26M
Series A (2024): $26M with participation from RH Capital, AXA IM ALTS - Real Assets, and Avestria Ventures Management
Series A (2024): $26M led by RH Capital, AXA IM ALTS - Real Assets, and Avestria Ventures Management
Key Investors in Novocuff
RH Capital
RH Capital is a dedicated venture capital firm focused on identifying and supporting high-potential companies within the private equity landscape.
AXA IM ALTS - Real Assets
AXA IM Alts is a global leader in alternative investments, managing extensive assets with a focus on sustainable value creation and long-term impact across diverse sectors.
Avestria Ventures Management
Avestria Ventures is a specialized VC firm that invests in early-stage life science companies, with a specific mandate to support women's health innovations and female-led ventures.
What's next for Novocuff?
With the successful closure of this Series A round, Novocuff is poised to enter a high-growth trajectory. The strategic roadmap likely includes expanding clinical trial footprints, enhancing manufacturing capabilities, and preparing for broader market entry. As the company continues to leverage its recent capital, the focus will remain on demonstrating the efficacy of its medical devices to healthcare providers and institutional stakeholders. The involvement of specialized venture capital firms suggests a long-term commitment to scaling the company's impact, with future milestones likely centered on regulatory approvals and the establishment of a sustainable commercial infrastructure to support widespread adoption in clinical settings.
See full Novocuff company page
